Medical Science News

RSS

Human brain processes predictable sensory input more efficiently

The human brain processes predictable sensory input more efficiently. Alink and colleagues based this conclusion on the characteristics of responses in the primary visual cortex. It is known that the primary visual cortex is critical for vision and that responses in this brain area create a map of what we are currently looking at.

16 Mar 2010

Link between potential hyper-activity of mTOR signalling pathway and cancer cells

The link between obesity and disease has been well documented. There's evidence now that obesity and cancer have a strong link, as they've shown in the United States at least 90,000 cancer deaths a year can be attributed to obesity. University of Alberta researcher Richard Lamb is on his way to understanding the correlation and it's a good example of how the scientific process works.

16 Mar 2010

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.

16 Mar 2010

CLC bio releases groundbreaking whole-genome de novo assembler

Today, CLC bio released a groundbreaking whole-genome de novo assembler that will assemble genomes of any size, including human and plant genomes on a single workstation computer. Equally important, CLC bio’s de novo assembler is the first assembler that enables molecular biologists to set up, adjust, and run their large genome de novo assemblies through a graphical user-interface.

16 Mar 2010

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

16 Mar 2010

A guide on ethics and neuroscience

As scientists continue to explore how the brain works, using ever more sophisticated technology, it seems likely that new findings will radically alter the traditional understanding of human nature.

16 Mar 2010

Study offers new possibilities for breast and other cancer therapies

Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals.

16 Mar 2010

Researchers gain new understanding of cilial protein Arl13b in Joubert syndrome

Researchers in Ireland have gained new understanding of the role played by the cilial protein Arl13b in Joubert syndrome (JS), a rare disorder characterized by developmental delay, mental retardation, and low muscle tone, among other symptoms.

16 Mar 2010

UCL scientists explore decision-making process of human brain

The more difficult the decision we face, the more likely we are not to act, according to new research by UCL scientists that examines the neural pathways involved in 'status quo bias' in the human brain.

16 Mar 2010

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

Research reveals molecular mechanism of DNA repair

New research led by scientists at the University of Essex has given an insight into how the body finds damage in the DNA code to repair it.

16 Mar 2010

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory Viral Infections being held in Taipei.

15 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Comparison study of genetic tests for ASD finds CMA with highest detection rate

The Autism Consortium, an innovative research, clinical and family collaboration dedicated to catalyzing research and enhancing clinical care for families with autism spectrum disorders (ASDs), announced today that the results of its comparison study of genetic testing methods for autism spectrum disorders is available from the journal Pediatrics through early online release in their eFirst pages today and will appear in the journal's April issue.

15 Mar 2010

Surprise stimulus temporarily blinds subsequent events

Reading this story requires you to willfully pay attention to the sentences and to tune out nearby conversations, the radio and other distractions. But if a fire alarm sounded, your attention would be involuntarily snatched away from the story to the blaring sound.

15 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Enzo Biochem, Inc. today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

15 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

Medical Science News

Human brain processes predictable sensory input more efficiently

Link between potential hyper-activity of mTOR signalling pathway and cancer cells

Concurrent use of proton-pump inhibitor and clopidogrel does not elevate cardiovascular risk

CLC bio releases groundbreaking whole-genome de novo assembler

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

A guide on ethics and neuroscience

Study offers new possibilities for breast and other cancer therapies

Researchers gain new understanding of cilial protein Arl13b in Joubert syndrome

UCL scientists explore decision-making process of human brain

Gene defects could become targets for new personalised treatments for bowel cancer

Research reveals molecular mechanism of DNA repair

TCAD therapy superior to double combinations and monotherapy against influenza viruses

Regado Biosciences announces first successful subcutaneous application of an aptamer

Comparison study of genetic tests for ASD finds CMA with highest detection rate

Surprise stimulus temporarily blinds subsequent events

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News